Outcomes of BCG vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancer

膀胱切除术 医学 膀胱癌 危险系数 倾向得分匹配 比例危险模型 泌尿科 内科学 累积发病率 回顾性队列研究 置信区间 入射(几何) 队列 癌症 肿瘤科 外科 物理 光学
作者
Pietro Scilipoti,Mattia Longoni,Mario de Angelis,Paolo Zaurito,Aleksander Ślusarczyk,Francesco Soria,Benjamin Pradere,Wojciech Krajewski,David D‘Andrea,Andrea Mari,Francesco Del Giudice,Renate Pichler,José Daniel Subiela,Gautier Marcq,Andrea Gallioli,Luca Afferi,Riccardo Mastroianni,Giuseppe Simone,Simone Albisinni,Laura S. Mertens
出处
期刊:BJUI [Wiley]
卷期号:136 (1): 47-54 被引量:7
标识
DOI:10.1111/bju.16675
摘要

Objective To assess the oncological outcomes of patients with high‐risk (HR) and very high‐risk (VHR) non‐muscle‐invasive bladder cancer (NMIBC) treated with upfront radical cystectomy (RC) vs Bacillus Calmette–Guérin (BCG) instillations from a contemporary European multicentre cohort. Patients and Methods We conducted a retrospective analysis of 1491 patients diagnosed with HR‐ or VHR‐NMIBC from a European multicentre database between 2015 and 2024. Patients were included if they received either upfront RC or at least five doses of BCG. A 1:1 propensity score matching (PSM) according to clinically relevant variables was applied. Progression was defined as muscle‐invasive or metastatic disease. Cumulative incidence plots and multivariable competing risk regression models addressing cancer‐specific mortality (CSM) were fitted. Results Among the 1221 patients with HR‐ ( n = 1221 [90%]) or VHR‐NMIBC ( n = 121 [10%]), 87 (7.1%) underwent upfront RC. The median follow‐up was 2.6 years. After PSM (87 vs 87 patients), the 5‐year CSM rate was similar in patients treated with BCG (13%) vs their upfront RC counterparts (16%) (hazard ratio: 1.77, 95% confidence interval [CI] 0.66–4.73; P = 0.3). Of the 1134 patients who initially received BCG, 73 (6.6%) eventually required delayed RC, with 34 (47%) progressing to muscle‐invasive bladder cancer before delayed RC. The 3‐year CSM rate was comparable in upfront RC (13%) vs delayed RC (11%) among non‐progressing patients ( P = 0.3). However, patients who progressed before delayed RC had worse 3‐year CSM relative to those who did not (13% vs 31%, hazard ratio: 0.32, 95% CI 0.13–0.83; P = 0.018). Conclusion Within a European cohort of patients with HR‐ and VHR‐NMIBC, upfront RC was rarely performed. Patients treated with BCG did not exhibit a CSM disadvantage relative to their upfront RC counterparts. After matching, long‐term CSM was similar between BCG therapy and upfront RC. Delayed RC, led to worse outcomes if performed after progression, but matched upfront RC when performed before progression, underscoring importance of timely surgery.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft应助科研通管家采纳,获得10
刚刚
刚刚
共享精神应助科研通管家采纳,获得10
1秒前
Akim应助kyt采纳,获得10
1秒前
Lucas应助科研通管家采纳,获得10
1秒前
Baihuashan完成签到 ,获得积分10
1秒前
1秒前
在水一方应助科研通管家采纳,获得10
1秒前
1秒前
Jasper应助科研通管家采纳,获得10
1秒前
王青文完成签到,获得积分10
1秒前
molihuakai应助科研通管家采纳,获得20
1秒前
1秒前
欣喜觅波发布了新的文献求助10
2秒前
老刀完成签到,获得积分10
2秒前
七颗茶香豆应助NAUGHTY采纳,获得10
2秒前
2秒前
Waiting发布了新的文献求助10
2秒前
整齐问梅完成签到,获得积分10
2秒前
赵三岁完成签到,获得积分10
2秒前
devilito发布了新的文献求助10
2秒前
乔治完成签到,获得积分10
3秒前
liuhua完成签到,获得积分10
3秒前
Bonny完成签到,获得积分10
3秒前
丘比特应助科研通管家采纳,获得10
3秒前
酷波er应助科研通管家采纳,获得10
3秒前
3秒前
Akim应助科研通管家采纳,获得10
3秒前
3秒前
所所应助科研通管家采纳,获得10
3秒前
天天应助科研通管家采纳,获得10
3秒前
Sowoozoo完成签到 ,获得积分10
3秒前
思源应助科研通管家采纳,获得10
4秒前
演化的蛙鱼完成签到,获得积分10
4秒前
独特的幼菱完成签到,获得积分10
4秒前
4秒前
Ava应助科研通管家采纳,获得10
4秒前
DOC_XIONG应助科研通管家采纳,获得10
4秒前
4秒前
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 800
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
CLSI VET01S-2024 Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals (7th Ed) 500
DIPPR Project 801 - Full Version 380
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 化学工程 工程类 有机化学 物理 复合材料 生物化学 内科学 细胞生物学 基因 遗传学 免疫学 冶金 光电子学 癌症研究
热门帖子
关注 科研通微信公众号,转发送积分 7766283
求助须知:如何正确求助?哪些是违规求助? 9310196
关于积分的说明 20315381
捐赠科研通 7351072
什么是DOI,文献DOI怎么找? 3315052
关于科研通互助平台的介绍 2464580
邀请新用户注册赠送积分活动 2329619